



**Tissue Regenix Group  
Human Tissue Joint Venture Agreement**

# Overview

## Summary

Tissue Regenix has entered its first Joint Venture Agreement creating GBM-V Tissue Bank in Rostock, Germany. This will allow Tissue Regenix to licence its patented dCELL<sup>®</sup> technology, producing and distributing the first human tissue dCELL<sup>®</sup> products throughout Europe.

## Highlights

- FIRST Joint Venture for the Tissue Regenix Group
- FIRST commercial licence for the dCELL<sup>®</sup> Human Heart Valve
- FIRST Agreement following new partnership business model
- FIRST dCELL<sup>®</sup> Human Tissue products within the EU (subject to regulatory approval)
- The initial licences will cover Human Heart Valves and also DermaPure<sup>®</sup>
- Tissue Regenix to make an initial investment of €250,000 over the next two years to fund development and distribution


# Rationale

- Allows Tissue Regenix to support and work with an accomplished, experienced group of tissue medicine professionals
- Produce and distribute these products, in line with stringent German, and wider EU requirements.
- Tissue Regenix's commercialisation strategy passes an important milestone, as it licences its patented dCELL<sup>®</sup> technology making available a potential portfolio of decellularised human tissue products.
- Ten years of pioneering clinical work by Professor Francisco da Costa in Brazil on decellularised human heart valves allows Tissue Regenix to be confident of the safety and success of this product and to agree this first licence.
- GBM-V will also be important in developing new human tissue applications of the dCELL<sup>®</sup> technology in partnership with Tissue Regenix.

# Business relationship

- Tissue Regenix will licence its patented dCELL<sup>®</sup> technology to GBM-V
- GTM-V will provide donated human tissue
- GBM-V will utilise dCELL<sup>®</sup> technology to treat Human Heart Valve tissue and human dermis, creating decellurised human tissue treatments
- GBM-V will work with Tissue Regenix to improve and refine the dCELL<sup>®</sup> process for these tissues, and look at the potential for other applications

# How will TRX and GBM-V work together



# What next?

- It is expected the first dCELL<sup>®</sup> Human Tissue will be distributed in Germany in 2017
- Wider European distribution expected to follow
- In the longer term, Tissue Regenix hopes to replicate this type of agreement in other countries with similar policies and procedures.